Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer

2014 ◽  
Vol 29 (9) ◽  
pp. 1744-1749 ◽  
Author(s):  
Yousuke Nakai ◽  
Hiroyuki Isayama ◽  
Hirofumi Kogure ◽  
Tsuyoshi Hamada ◽  
Osamu Togawa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Biliary Obstruction ◽  
Stent Migration ◽  
Malignant Biliary Obstruction ◽  
Metallic Stent ◽  
Covered Metallic Stent ◽  
Distal Malignant Biliary Obstruction

Management of distal malignant biliary obstruction with the ComVi stent, a new covered metallic stent

2009 ◽  
Vol 24 (1) ◽  
pp. 131-137 ◽  
Author(s):  
Hiroyuki Isayama ◽  
Takao Kawabe ◽  
Yousuke Nakai ◽  
Yukiko Ito ◽  
Osamu Togawa ◽  
...  
Keyword(s):  
Biliary Obstruction ◽  
Malignant Biliary Obstruction ◽  
Metallic Stent ◽  
Covered Metallic Stent ◽  
Distal Malignant Biliary Obstruction

Percutaneous use of ePTFE/FEP-covered metallic stent for palliation of malignant biliary obstruction

2014 ◽  
Vol 23 (6) ◽  
pp. 366-373
Author(s):  
Charles Edouard Zurstrassen ◽  
Aline Cristine Barbosa Santos ◽  
Chiang Jeng Tyng ◽  
João Paulo Matushita ◽  
Felipe Jose Coimbra ◽  
...  
Keyword(s):  
Biliary Obstruction ◽  
Malignant Biliary Obstruction ◽  
Metallic Stent ◽  
Covered Metallic Stent

scholarly journals Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer

2020 ◽  
Vol 08 (11) ◽  
pp. E1603-E1610
Author(s):  
Tsuyoshi Takeda ◽  
Takashi Sasaki ◽  
Takafumi Mie ◽  
Takaaki Furukawa ◽  
Ryo Kanata ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Risk Factor ◽  
Biliary Obstruction ◽  
Volume Index ◽  
Metallic Stent ◽  
Sems Placement ◽  
Borderline Resectable ◽  
Pancreatic Volume ◽  
Novel Risk Factors

Abstract Background and study aims Self-expandable metallic stents (SEMS) are now widely used even for patients with borderline resectable (BR) pancreatic cancer (PC), as neoadjuvant therapy has become common. Therefore, we conducted this study to evaluate safety of SEMS placement in the population including BR PC and to explore risk factors for recurrent biliary obstruction (RBO), pancreatitis, and cholecystitis. Patients and methods We retrospectively investigated consecutive patients with PC who received initial SEMS between January 2015 and March 2019. We compared time to RBO (TRBO), causes of RBO, and stent-related adverse events (AEs) according to resectability status. Univariate and multivariate analyses were performed to explore risk factors for TRBO, pancreatitis, and cholecystitis. Results A total of 135 patients were included (BR 31 and unresectable [UR] 104). Stent-related AEs occurred in 39 patients: pancreatitis 14 (mild/moderate/severe 1/6/7), cholecystitis 12, and non-occluding cholangitis 13. TRBO, causes of RBO, and stent-related AEs were not significantly different according to resectability status. Overall rate of RBO was higher in UR PC due to the longer follow-up period. Sharp common bile duct (CBD) angulation was an independent risk factor for short duration of TRBO. High pancreatic volume index and SEMS of high axial force were independent risk factors for pancreatitis, whereas tumor involvement to orifice of cystic duct was the only risk factor for cholecystitis. Conclusions We demonstrated that SEMS can be safely deployed even in patients with BR PC. Sharp CBD angulation and high pancreatic volume index were identified as novel risk factors for RBO and pancreatitis, respectively, after SEMS placement.

scholarly journals Risk Factors of Pancreatitis after Percutaneous Transhepatic Biliary Stent Implantation in Patients with Distal Malignant Biliary Obstruction

2020 ◽  
Author(s):  
Nan Jia ◽  
Zhihui Chang ◽  
Zhaoyu Liu
Keyword(s):  
Risk Factors ◽  
Stent Implantation ◽  
Biliary Obstruction ◽  
Protective Factor ◽  
Malignant Biliary Obstruction ◽  
Biliary Stent ◽  
Duodenal Papilla ◽  
Postoperative Pancreatitis ◽  
Preoperative Administration ◽  
Distal Malignant Biliary Obstruction

Abstract Purpose Percutaneous transhepatic biliary stent implantation (PTBS) has been widely used in the treatment of malignant obstructive jaundice (MBO)，which is an effective palliative therapy. The goal of the research was to explore the risk factors of postoperative pancreatitis in patients who had received PTBS.Materials and Methods This study retrospectively included 248 patients with distal malignant biliary obstruction (DMBO) who received PTBS from 2014 to 2019. The risk factors of postoperative pancreatitis such as clinical characteristics, laboratory and stent variables were evaluated by logistic regression analysis.Results Pancreatitis occurred in 51 (20%) patients, all of whom were mild pancreatitis. Multivariate analysis showed that stent implantation across the duodenal papilla, preoperative (within 3 days) administration of proton pump inhibitors (PPIs) were independent risk factors that related to pancreatitis (OR =13.242, 95% CI: 1.729–101.405; P = 0.013; OR =2.113, 95% CI: 1.024–4.36; P = 0.043, respectively), while preoperative administration of antibiotics was a protective factor (OR =0.466, 95% CI: 0.226–0.961; P = 0.039).Conclusion Patients with DMBO who underwent PTBS across the duodenal papilla were more likely to developing postoperative pancreatitis. Preoperative (within 3 days) administration of PPIs was also an independent risk factor for postoperative pancreatitis. Furthermore, preoperative administration of antibiotics may lower the risk of pancreatitis.

Sign in / Sign up

Export Citation Format

Share Document